Following two Phase 3 clinical studies which demonstrated efficacy and safety, the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) inhibitors. 
RINVOQ® is a selective JAK inhibitor that showed greater inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2. It is available in a once daily 15 mg dose. 
“Many adults still struggle to find a treatment option that helps them lower their disease activity,” said Iain McInnes, professor of medicine and Versus Arthritis professor of rheumatology at University of Glasgow, U.K., and lead investigator of the SELECT-PsA 1 trial. “With this FDA approval, RINVOQ has the potential to help more people find meaningful relief from the signs and symptoms of psoriatic arthritis that they see and feel and to help reach their treatment goals.” 
This is the second FDA-approved indication for RINVOQ®. It was previously approved for rheumatoid arthritis in 2019.